New developments in contraceptive drugs for use by women

Bibliography

• LIPPES J: Quinacrine sterilization:the imperative need for american clinical trials. Feral. Stern. (2002)77:1106–1109.
   PubMed Web of Science ®Google Scholar
• GUHA SK, SINGH G, SCRIVASTAVA A et al.: Two-year clinical efficacy trial with dose variations of a vas deferens injectable contraceptive for the male. Contraception (1998) 58:165–174.
   Web of Science ®Google Scholar
• VAN LOOK PFA: Contraceptives of the future. In: Handbook of Family Planning and Reproductive Healthcare Glasier A, Gebbie A (Eds), Churchill Livingstone, Edinburgh, Scotland. (2000):397–398.
   Google Scholar
• PINCUS G: The control of fertility. Academic Press, New York, USA (1965).
   Google Scholar
• AKERLUND M, RODE A, WESTERGAARD J: Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 15011g desogestrel and either 30 p,g or 201.1g ethinyl oestradiol. Br. J. Obstet. Cynaecol. (1993) 100:832–838.
   PubMed Web of Science ®Google Scholar
• SPONA J, ELSTEIN M, FEICHTINGER W et al.: Shorter hormone free interval in combined oral contraceptives decreases follicular development. Br. Med. J. (1996) 54:1–74.
   Google Scholar
• ENDRIKAT J, CRONIN M, GERLINGER C, RUEBIG A, SCHMIDT W, DUSTERBERG B: Open, multi-centre comparison of efficacy cycle control and tolerability of a 23-day oral contraceptive regimen with 20 mg ethinyl estradiol and 75 mg gestodene and a 21-day regimen with 20 mg ethinyl estradiol and 150 mg desogestrel. Contraception (2001) 64:201–207.
   PubMed Web of Science ®Google Scholar
• GESTODENE STUDY GROUP 322: The safety and contraceptive efficacy of a 24-day low dose oral contraceptive regimen containing gestodene 601.1g and ethinyloestradiol 15 1.1g. Ear. Contracep. Reprod. Health Care (1999) 4(Suppl.):9–15.
   Google Scholar
• •A study of a combined pill containing 15 lig EE.
   Google Scholar
• FRUZETTI F, GENAZZANI AR, RICCI C, DE NEGRI F, BERSI C, CARMASSI F: A 12-month clinical investigation with a 24-day regimen containing 15p,g ethinyloestradiol plus 60p,g gestodene with respect to haemostasis and cycle control. Contraception (2001) 63:303–307.
   PubMed Web of Science ®Google Scholar
• THE MIRCETTE STUDY GROUP: An open-label, multicentre,noncomparative safety and efficacy study of Mircette TM, a low-dose estroen-progestin oral contraceptive. Am. Obstet. Cynecol (1998) 179:S2–S8.
   PubMed Web of Science ®Google Scholar
• KILLICK SA, FITZGERALD C, DAVIS A:Ovarian activity in women taking an oral contraceptive containing 20 1.1g ethinyl estradiol and 150 i.tg desogestrel: effects of low estrogen doses during the hormone-free interval. Am. Obstet. Cynecol (1998) 179:S18–S24.
   Google Scholar
• DEN TONKELAAR I, ODDENS 13J: Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status and contraceptive use and hormone replacement therapy use. Contraception (1999) 59:357–362.
   PubMed Web of Science ®Google Scholar
• LOUD ON NB, FOXWELL M, POTTS DM, GUILD AL, SHORT RV: Acceptability of an oral contraceptive that reduces frequency of menstruation : the tri-cycle pill regime. Br. Med. J. (1977) 11:487–490.
   Google Scholar
• MILLER L, KNOTTER KM: Menstrual reduction with extended use of combined oral contraceptive pills: randomized controlled trial. Obstet. Cynecol (2001) 98:771–778.
   Web of Science ®Google Scholar
• KAUNITZ AM: Menstruation:choosing whetherand when. Contraception (2000) 62:277–284.
   PubMed Web of Science ®Google Scholar
• •A review discussing COC use to induce amenorrhoea.
   Google Scholar
• BOYD RA, ZEGARAC AE, POSVAR EL, FIACK MR: Minimal androgenic activity of a new oral contraceptive containing norethindrone acetate and graduated dose of ethinyl estradiol. Contraception (2001) 63:71–76.
   PubMed Web of Science ®Google Scholar
• SKEGG DCG: Third Generation Oral Contraceptives. Br. Med. (2000) 321:190–191.
   PubMed Web of Science ®Google Scholar
• KUMAR N, KOIDE SS, TSONG Y-T, SUNDARAM K: Nestorone® : a progestin with a unique pharmacological profile. Steroids (2000) 65:629–636.
   PubMed Web of Science ®Google Scholar
• •A review of Nestorone.
   Google Scholar
• MUHN P, KRATTENMACHER R, BEIER S et al.: Drospirenone a novel progestogen with antimineralocorticoid and anti androgenic activity. Contraception (1995) 51:99–110.
   PubMed Web of Science ®Google Scholar
• OELKERS W: Drospirenone - a new progestogen with antimineralocorticoid activity, resembling natural progesterone. Lin: I Contracept. Reprod. Health Care (2000) 5\(Suppl. 3):17–26.
   Google Scholar
• FOIDART JM, WUTTKE W, BOUW GM, GERLINGER C, HEITHECKER R: A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Ear: J. Contracept. Reprod. Health Care (2000) 5:124–134.
   PubMedGoogle Scholar
• •A comparison of combined pills containing desogestrel or drospirenone.
   Google Scholar
• VASILAKIS-SCARAMOZZA C, JICK H: Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet (2001) 358:1427–1429.
   PubMed Web of Science ®Google Scholar
• SITRUK-WARE R: Progestogens in hormone replacement therapy; new molecules, risks and benefits. Menopause (2002) 9:6–15.
   PubMed Web of Science ®Google Scholar
• BAZIN B, THEVERIOT R, BURSAUX C, PARIS J: Effect of nomegestrol acetate, a new 19-nor-progesterone derivative, on pituitary function in women. Br. .1. Obstet. Cynaecol (1987) 94:119–1204.
   Google Scholar
• ZHANG Z, LUNDEEN SG, ZHU Y, CARVER JM, WINNEKER C: In vitro chracterization of trimegestone : a new potent and selective progestin. Steroids (2000) 65:637–643.
   PubMed Web of Science ®Google Scholar
• RICE CF, KILLICK SR, DIEBEN T, COELINGH BENNINK HC: A comparison of the inhibition of ovulation achieved by desogestrel 751.1g and levonorgestrel 301.1„g daily. Hum. Reprod. (1999) 14:982–985.
   PubMed Web of Science ®Google Scholar
• MEIRIK 0: Implantable contraceptives for women. Contraception (2002) 65:1–3.
   PubMed Web of Science ®Google Scholar
• CROXATTO HB: Progestin implants for female contraception. Contraception (2002) 65:15–19.
   PubMed Web of Science ®Google Scholar
• •An overview of implants.
   Google Scholar
• CROXATTO HB, URBANCSEK J, MASSAI R, COELINGH-BENNINK H, VAN BEEK A. IMPLANON STUDY GROUP: A mukicentre efficacy and safety study of the single contraceptive implant Implanon. Hum. Reprod. (1999) 14:976–981.
   Google Scholar
• DIAZ S, SCHIPPACASSA V, PEREZ Met al.: Clinical trial with Nestorone subdermal contraceptive implants. Contraception (1995) 51:33–38.
   Google Scholar
• SIVIN I, MOO-YOUNG F: Recent developments in contraceptive implants at the Population Council. Contraception (2002) 65:113–119.
   PubMed Web of Science ®Google Scholar
• MASSAI RM, DIAZ S, QUINTEROS E et al.: Contraceptive efficacy and clinical performance of Nestorone implants in post partum women. Contraception (2001) 64:369–376.
   PubMed Web of Science ®Google Scholar
• COUTINHO E, DE SOUZA JC, ATHAYDE C et al: Multicentre clinical trial on the efficacy and acceptability of a single contraceptive implant of nomegestrol acetate. Contraception (1996) 53:121–125.
   PubMed Web of Science ®Google Scholar
• TIMMER C, MULDERS TMT: Pharmacokinetics of etonorgestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin. Pharmacokinet. (2000) 39:233–242.
   PubMed Web of Science ®Google Scholar
• ROUMEN FJME, APTER D, MULDERS TMT, DIEBEN TOM: Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonorgestrel and ethinyloestradiol. Hum. Reprod. (2001) 16:469–475.
   PubMed Web of Science ®Google Scholar
• •Clinical trial of the combined contraceptive vaginal ring.
   Google Scholar
• BJARNADOTTIR RJ, TUPPURAINEN M, KILLICK SR: Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol. Am. Obstet. Cynecol (2002) 186:389–395.
   PubMed Web of Science ®Google Scholar
• WEISBERG E, FRASER IS, MISHELL DR,LACARRA M, DARNET P, JACKANICZ TM: A comparative study of two contraceptive vaginal rings releasing norethindrone acetate and differing doses of ethinyl oestradiol. Contraception (1999) 59:305–310.
   PubMed Web of Science ®Google Scholar
• ALVAREZ-SANCHEZ F, BRACHE V, JACKANICZ T, FAUNDES A: Evaluation of four different contraceptive vaginal rings : steroid serum levels, luteal activity, bleeding control and lipid profiles. Contraception (1992) 46:387–391.
   PubMed Web of Science ®Google Scholar
• BRACHE V, MISHELL DR, LAHTEENMAKI P et al.: Ovarian function during use of vaginal rings delivering three difference doses of Nestorone®. Contraception (2001) 63:257–261.
   PubMed Web of Science ®Google Scholar
• WORLD HEALTH ORGANIZATION TASK FROCE ON LONG-ACTING SYSTEMIC AGENTS FOR FERTILITY REGULATION: A multicentred Phase III comparative study of two hormonal contraceptive preparations given once-a-month by intramuscular injection : contraceptive efficacy and side effects. Contraception (1988) 37:1–20.
   PubMed Web of Science ®Google Scholar
• KAUNITZ AM, GARCEAU RJ, CROMIE MA, LUNELLE STUDY GROUP: Comparative safety, efficacy and cycle control of Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension) and Ortho-Novum 7/7/7 oral contraceptive (norethindrone/ethinyl estradiol triphasic). Contraception (1999) 60:179–187.
   PubMed Web of Science ®Google Scholar
• AUDET MC, MOREAN M, KOLTUN WD et al.: for the ORTHO/EVRA/EVRA study group: Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch versus an oral contraceptive. A randomized controlled trial. JA/VIA (2001) 285:2347–2354.
   Google Scholar
• •Clinical trial of the combined contraceptive patch.
   Google Scholar
• WILDEMEERSCH D, SCHACHT E: Endometrial suppression with a new 'frameless' levonorgestrel releasing intrauterine system in perimenopausal and postmenopausal women: a pilot study. Maturitas (2000) 36:63–68.
   PubMed Web of Science ®Google Scholar
• WILDEMEERSCH D, SCHACHT E, WILDEMEERSCH P: Treatment of primary and secondary dysmenorrhoea with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study. Eur. I Contracep. Reprod. Health Care (2001) 6:192–198.
   PubMed Web of Science ®Google Scholar
• JANSSEN CAH, SCHOLTEN PC, HEINTZ PM: The effect of low-dose 3-keto-desogestrel added to a copper-releasing intrauterine contraceptive device on menstrual loss : a double-blind dose-finding placebo-controlled study. Am. Obstet. Cynecol (2000) 182:575–581.
   PubMed Web of Science ®Google Scholar
• HODGEN GD: Antiprogestins : The political chemistry of RU486. Fertil. (1991) 56:394–395.
   PubMed Web of Science ®Google Scholar
• GLASIER A, THONG KJ, DEWAR M, MACKIE M, BAIRD DT: Comparison of mifepristone and high dose oestrogen-progestogen for emergency post coital contraception. N Engl. .1. Med.(1992) 327:1041–1044.
   PubMed Web of Science ®Google Scholar
• WEBB AMC, RUSSEL J, ELSTEIN M: Comparison of the Yuzpe regime, danazol and mifepristone in oral post-coital contraception. Br. Med. J. (1992) 305:927–931.
   PubMed Web of Science ®Google Scholar
• TASK FORCE ON POSTOVULATORY METHODS OF FERTILITY REGULATION: Comparison of three single doses of mifepristone as emergency contraception: a randomised trial. Lancet (1999) 353:697–702.
   PubMed Web of Science ®Google Scholar
• •Effectiveness of mifepristone as an emergency contraceptive.
   Google Scholar
• CROXATTO HB, SALVATIERRA AM, CROXATTO HD, FUENTEALBA B: Effects of continuous treatment with low dose mifepristone throughout one menstrual cycle. Hum. Reprod. (1993) 8:201–207.
   PubMed Web of Science ®Google Scholar
• LEDGER WL, SWEETING VM, HILLIERH, BAIRD DT: Inhibition of ovulation by low-dose mifepristone (RU486). Hum. Rep. (1992) 7:945–950.
   PubMed Web of Science ®Google Scholar
• CAMERON ST, THONG KJ, BAIRD DT: Effect of daily low dose mifepristone on the ovarian cycle and on the dynamics of follicle growth. Clin. Endocrin. (1995) 43:407–414.
   PubMed Web of Science ®Google Scholar
• BROWN A, CHENG L, LIN S, BAIRD DT: Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: A double-blind randomized control trial of 2 and 5 mg per day for 120 days.' Clin. Endocrinol Metab (2002) 87:63–70.
   Google Scholar
• •An efficacy study of low-dose daily mifepristone.
   Google Scholar
• CROXATTO HB, KOVACS L, MASSAI R, RESCH BA: Effects of long-term low-dose mifepristone on reproductive function in women. Hum. Reprod. (1998)13:793–798.
   PubMed Web of Science ®Google Scholar
• GEMZELL-DANIELSSON K, SWAHN ML, WESTLUND P, JOHANNISSON E, SEPPALA M, BYDEMAN M: Effect of low daily doses of mifepristone on ovarian function and endometrial development. Hum. Reprod. (1997)12:124–131.
   PubMed Web of Science ®Google Scholar
• MARIONS L, VISKI S, GEMZELL-DANIELSSON K et al.: Contraceptive efficacy of daily administration of 0.5 mg mifepristone. Hum. Reprod. (1999) 14:2788–2790.
   Google Scholar
• •An efficacy study of very low-dose daily mifepristone.
   Google Scholar
• SPITZ IM, CROXATTO HB, ROBBINS A: Antiprogestins: mechanism of action and contraceptive potential. Ann. Rev Pharmacol Toxicol (1996) 36:47–81.
   PubMed Web of Science ®Google Scholar
• CHEN X, XIAO B: Effect of once weekly administration of mifepristone on ovarian function in women. Contraception (1997) 56:175–180.
   PubMed Web of Science ®Google Scholar
• GEMZELL-DANIELSSON K, WESTLUND P, JOHANNISSON E, SWAHN M-L, BYDEMAN M, SEPPALA M: Effect of low weekly doses of mifepristone on ovarian function and endometrial development. Hum. Reprod. (1996)11:256–264.
   PubMed Web of Science ®Google Scholar
• MARIONS L, GEMZELL-DANIELSSON K, SWAHN M-L, BYDEMAN M: Contraceptive efficacy of low doses of mifepristone. Feral Steil]. (1998) 70:813–816.
   PubMed Web of Science ®Google Scholar
• •An efficacy study of once-weekly mifepristone.
   Google Scholar
• HAPANGAMA DK, GLASIER AF, BROWN A, BAIRD DT: Feasibility of administering mifepristone as a once a month contraceptive pill. Hum. Reprod. (2001) 16:1145–1150.
   PubMed Web of Science ®Google Scholar
• •An efficacy study of once-monthly mifepristone and useful review of the literature.
   Google Scholar
• GEMZELL-DANIELSSON K, SWAHN ML, SVALANDER P AND BYGDEMAN M: Early Luteal phase treatment with mifepristone (RU 486) for fertility regulation. Hum. Reprod. (1993) 8:870–873.
   PubMed Web of Science ®Google Scholar
• HAPANGAMA DK, GLASIER AF, BAIRD DT: Non-compliance among a group of women using a novel method of contraception. Feral Steril. (2001) 76:1196–1201.
   PubMed Web of Science ®Google Scholar
• KEKKONEN R, ALFTHAN H, HAUKKAMAA M, HEIKINHEIMO 0, LUUKKAINEN T, LAHTEENMAKI P: Interference with ovulation by sequential treatment with the antiprogesterone RU486 and synthetic progestin. Feral Steil] (1990) 53:747–750.
   PubMed Web of Science ®Google Scholar
• KEKKOKEN R, LAHTEENMAKI P, LUUKKAINEN T, TUOMINEN J: Sequential regimen of the antiprogesterone RU486 and synthetic progestin for contraception. Feral Steril. (1993) 60:610–615.
   PubMed Web of Science ®Google Scholar
• KEKKONEN R, CROXATTO HB, LAHTEENMAKI P, SALVATIERRA AM, TUOMINEN J: Effects of intermittent antiprogestin RU486 combined with cyclic medroxyprogesterone acetate on folliculogenesis and ovulation. Hum. Reprod. (1995) 10:287–292.
   PubMed Web of Science ®Google Scholar
• CROXATTO HB, MASSAI MR, SALVATIERRA AM, FUENTEALBA B, CROXATTO HD, LAHTEENMAKI P: Effects of a sequential regimen of mifepristone-medroxyprogesterone acetate on ovarian function, endometrial development and hormonal parameters. Contraception (1996) 54:79–86.
   PubMed Web of Science ®Google Scholar
• CROXATTO HB, SALVATIERRA AM, FUENTEALBA B, MASSAI R: Contraceptive potential of a mifepristone-nomegestrol acetate sequential regimen in women. Hum. Reprod. (1998) 13:3297–3302.
   PubMed Web of Science ®Google Scholar
• CHENG L, ZHUH, WANG A, REN F, CHEN J, GLASIER A: Once a month administration of mifepristone improves bleeding patterns in women using subdermal contraceptive implants releasing levonorgestrel. Hum. Rep. (2000) 15:1969–1972.
   PubMed Web of Science ®Google Scholar
• •A study of mifepristone to improve bleeding patterns with LNG implants.
   Google Scholar
• KLOOSTERBOER HJ, DECKERS GH, SCHOONEN WJ: Pharmacology of two new very selective antiprogestagens: Org 31710 and Org 31806. Hum. Reprod. (1994) 9:47–52.
   PubMed Web of Science ®Google Scholar
• VAN HEUSDEN AM, KILLICK SR, COELINGH BENNINK HJT, FAUSER BCJM: Single monthly administration of the anti-progestagen Org 31710 in users of the 751.1g desogestrel progestagen-only pill: effects on pituitary ovarian activity. Hum. Reprod. (2000) 15:629–636.
   Google Scholar
• PASSARO M, PIQUION J, MULLEN N et al.: Safety and luteal phase effects of the antiprogestin CDB - 2914 in normally cycling women. Proceedings of the 79th meeting of the Endocrine Society (1997) Endocrine Society, Minneapolis, USA.
   Google Scholar
• STRATTON P, HARTOG B, HAJIZADEN N et al: A single mid-follicular dose of CDB - 2914, a new antiprogestin inhibits folliculogenesis and endometrium in normally cycling women. Hum. Reprod. (2000) 15:1092–1099.
   PubMed Web of Science ®Google Scholar
• CHWALISZ K, BRENNER RIVI, FUHRMANN UU, HESS-STUMPP H, ELGER W: Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium. Steroids (2000) 65:741–751.
   PubMed Web of Science ®Google Scholar
• •An overview of progesterone antagonists and receptor modulators.
   Google Scholar
• HUIRNE JAF, LAMBALK CB: Gonadotrophin-releasing hormone — receptor antagonists. Lancet (2001) 358:1793–1803.
   PubMed Web of Science ®Google Scholar
• LAL J, ASTHANA OT, NITYANAND S, GUPTA RC: Pharmacokinetics of centchroman in healthy female subjects after oral administration. Contraception (1995) 52:297–300.
   PubMed Web of Science ®Google Scholar
• KAMBOJ VP, RAYS, DHAWAN BN: New Products: centchroman. Drugs Today(1992) 28:227–232.
   Google Scholar
• FENG H, SANDLOW JI, SPARKS AET,SANDRA A: Development of an immunocontraceptive vaccine. Current status.' Reprod. Med. (1999) 44:759–765.
   PubMed Web of Science ®Google Scholar
• TALWAR TP: Fertility regulating and immunotherapeutic vaccines reaching human trials stage. Hum. Reprod. Update (1997) 3:301–310.
   PubMed Web of Science ®Google Scholar
• SINGH M, DAS SK, SURI Set al.: Regain of fertility and normality of progeny born during below protective threshold anti-body titres in women immunized with the HSD-hCG vaccine. Am. .1. Reprod. Immunol (1999) 39:395–398.
   Google Scholar
• HARRISON PF, ROSENFIELD A: Contraceptive technology and the state of science: New Horizons. In: Contraceptive research and development. National Academic Press, Washington DC, USA (1996):125–165.
   Google Scholar
• •A detailed review of both broad and detailed issues of contraceptive development.
   Google Scholar
• BAIRD DT, GLASIER A: Science, Medicine and the future; Contraception. Br. Med. (1999) 319:969–972.
   PubMed Web of Science ®Google Scholar
• •A succinct review of the prospects of contraceptive development for the next ten years.
   Google Scholar